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Introduction
Juvenile idiopathic arthritis (JIA) is a severe disabling dis-
ease affecting paediatric population. 507 children with JIA
are monitored in Chelyabinsk region. Oligo-articular and
poly-articular types of JIA are often associated with affec-
tion of eyes (uveitis). In patients resistant to traditional
basic treatment (methotrexate and cyclosporine) F-alpha
inhibitors are recommended. Adalimumab, approved for
treatment of children older than 4 years in the Russian
Federation, is a treatment of choice in patients with JIA
associated with uveitis.
Objectives
Evaluate adalimumab effectiveness and safety in JIA
patients from Ural regions, Russia
Methods
11 JIA patients (age 8-17 years, mean age 12.2 years, 7 M,
4 F) were monitored. Disease duration: from 1 year to
11 years (mean 7.4 years). JIA diagnosis was based on the
ILAR criteria. Oligo-arthritis was reported in 5 children,
seronegative polyarthritis was reported in 4 children. Sys-
temic (without active systemic manifestations) and enthe-
sitis – associated JIA types were reported in 1 patient
each. 7 children had uveitis (bilateral uveitis was reported
in 6 of them). High disease activity was reported in 7
patients. X-ray activity (stages 1-2) was reported in 8 chil-
dren. All patients had functional class 2 disease. Metho-
trexate (15 mg/m2) was ineffective in all children. All
patients were receiving adalimumab (40 mg s/c EOW).
Treatment course duration: from 3 months to 3.5 years
(mean 1.3 years). ACR pedi criteria were used to evaluate
the disease activity and treatment efficacy.
Results
High disease activity (both joint syndrome and uveitis) was
reported in all children prior to adalimumab initiation.
Mean number of joints affected by severe arthritis: 5 [3, 8]
([25; 75%]). Number of joints with dysfunction: 4 [3, 8].
Mean ESR (as measured by Panchenkov’s method): 20 [15,
32] mm/hour; C-RP level: 25 [13, 40] g/l. Bilateral uveitis
was reported in 6 patients; unilateral uveitis was reported
in 1 patient. Number of affected eyes: 13. Uveitis was mild
and associated with cataract, resulting in lens replacement
in 11 affected eyes. Adalimumab treatment resulted in dis-
ease activity decrease in all patients.
Mean number of joints affected by active arthritis was
0 [0, 3] ([25; 75%]) (P = 0.003). Number of joints with
function disorder – 0 [0, 3] (P = 0.003). Mean ESR level:
4 [2, 15] mm/hour (P = 0.005), C-RP level: 6.5 [3; 15] g/l
(P = 0.008). CHAQ function index: 0.19 [0; 0.5] (P =
0.003). Investigator’s assessment of disease activity
(VAS): 20 [15, 30] (P=0.003). Patients/parents assessment
of disease activity (VAS): 20 [20, 30] (P = 0.003). Clinical
remission (ACR pedi criteria ≥90%) was reported in 8
patients within 3-6-12 months of treatment. 2 patients
were lost for contact within 3 and 6 months of treatment;
last reported efficacy was 50%. Insufficient efficacy was
reported only in 1 patient with systemic JIA (50% within
2.5 treatment years), resulting in treatment regimen
change. Remission of uveitis within 3 months of treat-
ment was reported in 2 children; remission within
6 months of treatment was reported in 3 children. Signif-
icant decrease of uveitis activity was reported in
2 children.
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Adverse event (transient myositis) was reported in
1 patient; treatment withdrawal was not required.
Conclusion
In patients with JIA, including uveitis-associated cases,
adalimumab treatment was highly effective and safe. Clini-
cal remission was achieved in 70% of children. Disease
activity decrease was reported in 100% of patients. No
severe adverse events were reported.
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